Elysium Health Stock

Scientific health products

Sign up today and learn more about Elysium Health Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.



Notable Investors

General Catalyst Partners


New York NY, US

Total Funding


About Elysium Health Stock

Elysium Health’s mission is to solve the challenges in health with science, to help people live healthier and longer. Elysium works directly with scientists, clinicians and health professionals worldwide the world to translate advances in science and technology into innovative health products that work. Our product development pipeline begins with research and development, continues with preclinical studies, and culminates with human clinical trials to demonstrate the safety and efficacy of products. Throughout this process, Elysium’s focus is to develop compounds found in nature that allow people to support their health proactively. Elysium is guided by a Scientific Advisory Board, which includes multiple winners of the Nobel Prize, as well as researchers and doctors who are experts in chemistry, physiology, neuroscience, complex chemical systems, biochemistry, and many other fields of study. Basis, Elysium Health’s first product, is a proprietary formulation of two ingredients designed to support long-term health at the cellular level. Basis is clinically proven to increase NAD+ levels, which decline with age. NAD+ is required for energy creation, regulating circadian rhythms, maintaining healthy DNA, and hundreds of other biological functions. Learn more via our science journal Endpoints: https://endpoints.elysiumhealth.com


Funding History

October 2015$1.1M
October 2015$6.2M
October 2016$22.0M


CEO & Co-Founder

Eric Marcotulli

COO & Co-Founder

Dan Alminana

Chief Scientist & Co-Founder

Leonard Guarente

Chief Design Officer

Andrew Lin


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: